Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Julia Rotow
Advertisement
Articles by Dr. Julia Rotow
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Top 3 Takeaways From WCLC 2026 That Patients Should Know
2
New Myeloma Combo Cuts Risk of Relapse by Up to 72% — Here's What It Could Mean for You
3
A Gift from the Sea
4
Enhertu Delays Progression in HER2-Mutant Lung Cancer in Phase 3 Trial
5